Roche diabetes drug beats Byetta

Roche says that an experimental diabetes therapy in-licensed from France's Ipsen proved more effective than Eli Lilly's Byetta in lowering blood sugar in a late-stage trial. The full set of data will be released at an upcoming scientific meeting, but for now Roche says that taspoglutide worked better than Byetta after 24 weeks of therapy. Roche holds the rights to the drugs in all countries except France and Japan. Ipsen has the rights to co-promotion rights in France. Roche plans on seven more late-stage trials of the drug, which is a potential blockbuster. Story

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.